The winners from a widely anticipated shakeout in global credit markets will be defined by different qualities. Direct lenders expect size to be a decisive factor, while distress players prioritize nimbleness
Bain Capital’s entry into the Australian credit market was facilitated by three acquisitions over the course of three years. In 2013, it paid more than $300 million for a portfolio of corporate loans...
China-based data storage software services provider XSKY has raised a RMB320 million ($45 million) Series D led by China's State Owned Capital Venture Capital Fund.
CF PharmTech, a Chinese medical devices maker focused on innovative respiratory products, has raised a $50 million Series F round with support from CICC Capital.
Chinese insulin manufacturer Gan & Lee Pharmaceuticals, which counts Qiming Venture Partners and Goldman Sachs among its investors, raised RMB2.5 billion ($354 million) through an A-share IPO.
KKR has agreed to buy a 54% stake in Indian drug maker J.B. Chemicals & Pharmaceuticals for INR31.1 billion ($416 million) and made an open offer for an additional 26% of the company.